Literature DB >> 8818025

The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody.

A Usami1, A Ohtsu, S Takahama, T Fujii.   

Abstract

The stability of human monoclonal antibody (C23), which is being developed as a passive immunotherapeutic agent against human cytomegalovirus, was investigated. C23 (about 2 mg ml-1) was incubated under sterile conditions for 14 days in buffers with different pH values (ranging from 4-10), in hydrogen peroxide solutions with different concentrations (0.01% or 0.1%), and in saline at 8 degrees C or 37 degrees C. Samples were collected on days 0, 3, 7 and 14, and various physicochemical or biological methods were used to determine the changes in in C23. These methods included turbidity (absorbance at 408 nm and transmittance at 580 nm), pH, size-exclusion high performance liquid chromatography (HPLC), hydroxyapatite HPLC, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, isoelectric focusing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and virus neutralization assay. Using these methods, the possible degradation processes of C23 were initially characterized. Deamidation, oxidation, fragmentation, covalent cross-links and aggregation were observed as major degradation routes. These results gave useful information for the manufacturing process and quality control of C23.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818025     DOI: 10.1016/s0731-7085(96)01721-9

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

Review 1.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

2.  Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration.

Authors:  Sorina Morar-Mitrica; Manasi Puri; Alexandra Beumer Sassi; Joshua Fuller; Ping Hu; George Crotts; Douglas Nesta
Journal:  MAbs       Date:  2015       Impact factor: 5.857

3.  Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates.

Authors:  Heather Franey; Stephen R Brych; Carl G Kolvenbach; Rahul S Rajan
Journal:  Protein Sci       Date:  2010-09       Impact factor: 6.725

4.  Buffer-dependent fragmentation of a humanized full-length monoclonal antibody.

Authors:  Branden A Salinas; Hasige A Sathish; Ambarish U Shah; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

5.  Fragmentation of a recombinant monoclonal antibody at various pH.

Authors:  Georgeen Gaza-Bulseco; Hongcheng Liu
Journal:  Pharm Res       Date:  2008-05-13       Impact factor: 4.200

6.  Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics.

Authors:  Gauri Rao; Vandana Iyer; Matthew P Kosloski; Dipak S Pisal; Eunkyoung Shin; C Russell Middaugh; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

7.  Development of orthogonal NISTmAb size heterogeneity control methods.

Authors:  Abigail Turner; Katharina Yandrofski; Srivalli Telikepalli; Jason King; Alan Heckert; James Filliben; Dean Ripple; John E Schiel
Journal:  Anal Bioanal Chem       Date:  2018-02-10       Impact factor: 4.142

8.  Investigation of the interactions of critical scale-up parameters (pH, pO2 and pCO2) on CHO batch performance and critical quality attributes.

Authors:  Matthias Brunner; Jens Fricke; Paul Kroll; Christoph Herwig
Journal:  Bioprocess Biosyst Eng       Date:  2016-10-17       Impact factor: 3.210

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.